Letters to the Editor

Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter’s transformation: results from the phase II GIVeRS trial

Hematology Unit, Bnai Zion Medical Center, Haifa, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa
Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, HaShomer, Israel; School of Medicine, Faculty of Medical and Health Sciences, Aviv University, Aviv
Department of Hematology, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University, Jerusalem
Hematology Unit, Bnai Zion Medical Center, Haifa, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa
School of Medicine, Faculty of Medical and Health Sciences, Aviv University, Aviv, Israel; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva
Department of Hematology, Emek Medical Center, Afula
School of Medicine, Faculty of Medical and Health Sciences, Aviv University, Aviv, Israel; Department of Hematology, Edith Wolfson Medical Center, Holon
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa
School of Medicine, Faculty of Medical and Health Sciences, Aviv University, Aviv, Israel; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva
School of Medicine, Faculty of Medical and Health Sciences, Aviv University, Aviv, Israel; Department of Hematology, Tel-Aviv Sourasky Medical Center. Tel-Aviv
Haematologica Early view May 7, 2026 https://doi.org/10.3324/haematol.2026.300749